BRD4 and fibrosarcoma: In vitro cell viability studies showed that cell lines from FET sarcomas (MLS 2645‐94, 402‐91 and 1765‐92, and EWS TC‐71) were more sensitive to BRD4 inhibition with the dual‐bromodomain inhibitor AZD5153 compared to HT1080 fibrosarcoma cells or normal fibroblasts (Fig. 4F).